[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-332209-105":3,"doc-detail-332209-en":81,"detail-sidebar-cat-0-en-105":98},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","rapidly-manufactured-cd276-car-t-cells-exhibit-enhanced-persistence-and-efficacy-in-pancreatic-cancer","Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efficacy in pancreatic cancer","","Pancreatic cancer remains one of the most lethal malignancies, and limited treatment options worsen outcomes. While CAR-T immunotherapy has advanced care for hematological cancers, success in solid tumors is constrained by insufficient tumor-specific antigens and by lengthy manufacturing timelines of 2–6 weeks. CD276 has emerged as a promising target for solid tumor therapy. This study assesses CD276 CAR-T and rapidly-manufactured CAR-T for anti-pancreatic cancer effects.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/rapidly-manufactured-cd276-car-t-cells-exhibit-enhanced-persistence-and-efficacy-in-pancreatic-cancer/332209/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/rapidly-manufactured-cd276-car-t-cells-exhibit-enhanced-persistence-and-efficacy-in-pancreatic-cancer/332209.png","ImageObject",300,407,{"name":42,"@type":43},"Maeve","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is CAR-T less effective in solid tumors like pancreatic cancer?","Question",{"text":63,"@type":64},"CAR-T success in solid cancers is limited mainly because solid tumors often lack highly tumor-specific antigens and the process has additional practical constraints for manufacturing.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the rapidly-manufactured CD276 CAR-T (Dash CAR-T) created?",{"text":68,"@type":64},"Dash CAR-T was developed by shortening the duration of ex vitro culture to reduce CAR-T manufacturing time. It carries a CAR structure including a 376.96 scFv sequence, CD8 hinge and transmembrane domain, and 4-1BB and CD3ζ intracellular domains.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the main findings on efficacy and persistence?",{"text":72,"@type":64},"CD276 CAR-T efficiently killed CD276-expressing solid cancer cells. Dash CAR-T was manufactured within 48–72 hours, showed a less-differentiated phenotype with strong proliferation in vitro, and demonstrated enhanced anti-pancreatic cancer efficacy and T-cell expansion in vivo while maintaining normal mouse condition except for the high-dose group.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},332209,1791075683,{"code":4,"msg":82,"data":83},"success",{"doc_id":79,"user_id":84,"nickname":42,"user_avatar":85,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":86,"file_id":87,"file_url":88,"file_type":89,"file_size":90,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":91,"language":92,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":93,"faqs":94,"seo_title":95,"seo_description":12,"update_tm":96,"read_time":97,"preview_page_count":4},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Deng et al. Journal of Translational Medicine (2024) 22:633  \n[https://doi.org/10.1186/s12967-024-05462-7](https://doi.org/10.1186/s12967-024-05462-7)  \nJournal of Translational Medicine  \n RESEARCH Open Access  \nRapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efficacy in pancreatic cancer  \nTian Deng1†, Yingzhi Deng1†, Shih‑Ting Tsao1†, Qinghui Xiong1†, Yue Yao1, Cuicui Liu2, Ming yuan Gu1, Fei Huang1* and Haiying Wang1*  \nAbstract  \nBackground Pancreatic cancer is one of the most lethal malignancies and the lack of treatment options makes it more deadly. Chimeric Antigen Receptor T‑cell (CAR‑T) immunotherapy has revolutionized cancer treatment and made great breakthroughs in treating hematological malignancies, however its success in treating solid can‑ cers remains limited mainly due to the lack of tumor‑specific antigens. On the other hand, the prolonged traditional manufacturing process poses challenges, taking 2 to 6 weeks and impacting patient outcomes. CD276 has recently emerged as a potential therapeutic target for anti‑solid cancer therapy. Here, we investigated the efficacy of CD276 CAR‑T and rapidly‑manufactured CAR‑T against pancreatic cancer.  \nMethods In the present study, CD276 CAR‑T was prepared by CAR structure carrying 376.96 scFv sequence, CD8 hinge and transmembrane domain, 4‑1BB and CD3ζ intracellular domains. Additionally, CD276 rapidly‑manufac‑ tured CAR‑T (named CD276 Dash CAR‑T) was innovatively developed by shortening the duration of ex vitro culture to reduce CAR‑T manufacturing time. We evaluated the anti‑tumor efficacy of CD276 CAR‑T and further compared the functional assessment of Dash CAR‑T and conventional CAR‑T in vitro and in vivo by detecting the immunophe‑ notypes, killing ability, expansion capacity and tumor‑eradicating effect of CAR‑T.  \nResults We found that CD276 was strongly expressed in multiple solid cancer cell lines and that CD276 CAR‑T could efficiently kill these solid cancer cells. Moreover, Dash CAR‑T was successfully manufactured within 48–72 hand the functional validation was carried out subsequently. In vitro, CD276 Dash CAR‑T possessed a less‑differentiated phenotype and robust proliferative ability compared to conventional CAR‑T. In vivo xenograft mouse model, CD276 Dash CAR‑T showed enhanced anti‑pancreatic cancer efficacy and T cell expansion. Besides, except for the high‑dose group, the body weight of mice was maintained stable, and the state of mice was normal.  \nConclusions In this study, we proved CD276 CAR‑T exhibited powerful activity against pancreatic cancer cells in vitro and in vivo. More importantly, we demonstrated the manufacturing feasibility, acceptable safety and superior  \n†Tian Deng, Yingzhi Deng, Shih‑Ting Tsao and Qinghui Xiong have contributed equally to the work.  \n*Correspondence:  \nFei Huang [huangfei@dashengbio.com](huangfei@dashengbio.com)[ ](huangfei@dashengbio.com)Haiying Wang [wanghaiying@dashengbio.com](wanghaiying@dashengbio.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/. The Creati","cbCaiaoCCJK8hVLe","https://ap.wps.com/l/cbCaiaoCCJK8hVLe","pdf",2236766,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Background","[{\"question\":\"Why is CAR-T less effective in solid tumors like pancreatic cancer?\",\"answer\":\"CAR-T success in solid cancers is limited mainly because solid tumors often lack highly tumor-specific antigens and the process has additional practical constraints for manufacturing.\"},{\"question\":\"How was the rapidly-manufactured CD276 CAR-T (Dash CAR-T) created?\",\"answer\":\"Dash CAR-T was developed by shortening the duration of ex vitro culture to reduce CAR-T manufacturing time. It carries a CAR structure including a 376.96 scFv sequence, CD8 hinge and transmembrane domain, and 4-1BB and CD3ζ intracellular domains.\"},{\"question\":\"What were the main findings on efficacy and persistence?\",\"answer\":\"CD276 CAR-T efficiently killed CD276-expressing solid cancer cells. Dash CAR-T was manufactured within 48–72 hours, showed a less-differentiated phenotype with strong proliferation in vitro, and demonstrated enhanced anti-pancreatic cancer efficacy and T-cell expansion in vivo while maintaining normal mouse condition except for the high-dose group.\"}]","Rapidly-manufactured CD276 CAR-T cells exhibit enhanced persistence and efficacy in pancreatic cancer | PDF",1789997325,30,{"code":4,"msg":82,"data":99},[100,104,108,112,117,122,127,129,134,137,141],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":101,"show_sort_weight":102,"slug":103},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":105,"show_sort_weight":106,"slug":107},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":109,"show_sort_weight":110,"slug":111},"Exam",70,"exam",{"id":113,"doc_module":4,"doc_module_name":25,"category_name":114,"show_sort_weight":115,"slug":116},5,"Comic",60,"comic",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":119,"show_sort_weight":120,"slug":121},6,"Technology",50,"technology",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":125,"slug":126},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":97,"slug":128},"research-report",{"id":130,"doc_module":4,"doc_module_name":25,"category_name":131,"show_sort_weight":132,"slug":133},9,"Religion & Spirituality",20,"religion-spirituality",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":135,"show_sort_weight":132,"slug":136},"World Cup","world-cup",{"id":138,"doc_module":4,"doc_module_name":25,"category_name":139,"show_sort_weight":138,"slug":140},10,"Lifestyle","lifestyle",{"id":142,"doc_module":4,"doc_module_name":25,"category_name":143,"show_sort_weight":113,"slug":144},19,"General","general"]